Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care - PubMed (original) (raw)
Practice Guideline
doi: 10.3109/13651501.2012.667114. Epub 2012 Apr 30.
Collaborators, Affiliations
- PMID: 22540422
- DOI: 10.3109/13651501.2012.667114
Practice Guideline
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care
Borwin Bandelow et al. Int J Psychiatry Clin Pract. 2012 Jun.
Erratum in
- Int J Psychiatry Clin Pract. 2012 Sep;16(3):242
- Int J Psychiatry Clin Pract. 2013 Feb;17(1):76
Abstract
Objective: Anxiety disorders are frequently under-diagnosed conditions in primary care, although they can be managed effectively by general practitioners.
Methods: This paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) for the treatment in primary care. The recommendations were developed by a task force of 30 international experts in the field and are based on randomized controlled studies.
Results: First-line pharmacological treatments for these disorders are selective serotonin reuptake inhibitors (for all disorders), serotonin-norepinephrine reuptake inhibitors (for some) and pregabalin (for generalized anxiety disorder only). A combination of medication and cognitive behavior/exposure therapy was shown to be a clinically desired treatment strategy.
Conclusions: This short version of an evidence-based guideline may improve treatment of anxiety disorders, OCD, and PTSD in primary care.
Similar articles
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders; Zohar J, Hollander E, Kasper S, Möller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J. Bandelow B, et al. World J Biol Psychiatry. 2008;9(4):248-312. doi: 10.1080/15622970802465807. World J Biol Psychiatry. 2008. PMID: 18949648 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD.
Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller HJ, Eriksson E, Fineberg NA, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman MA, Kim YK, Inoue T, Lim L, Masdrakis V, Menchón JM, Miguel EC, Nardi AE, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein DJ, Tsai SJ, Van Ameringen M, Vasileva A, Wang Z, Zohar J. Bandelow B, et al. World J Biol Psychiatry. 2023 Feb;24(2):118-134. doi: 10.1080/15622975.2022.2086296. Epub 2022 Jul 28. World J Biol Psychiatry. 2023. PMID: 35900217 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders.
Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N, Domschke K, Eriksson E, Fineberg NA, Hättenschwiler J, Hollander E, Kaiya H, Karavaeva T, Kasper S, Katzman M, Kim YK, Inoue T, Lim L, Masdrakis V, Menchón JM, Miguel EC, Möller HJ, Nardi AE, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein DJ, Tsai SJ, Van Ameringen M, Vasileva A, Wang Z, Zohar J. Bandelow B, et al. World J Biol Psychiatry. 2023 Feb;24(2):79-117. doi: 10.1080/15622975.2022.2086295. Epub 2022 Jul 28. World J Biol Psychiatry. 2023. PMID: 35900161 - [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G, Naja WJ, Pelissolo A. Ammar G, et al. Encephale. 2015 Jun;41(3):260-5. doi: 10.1016/j.encep.2013.11.002. Epub 2014 Nov 14. Encephale. 2015. PMID: 25439852 Review. French. - Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.
Zohar J, Westenberg HG. Zohar J, et al. Acta Psychiatr Scand Suppl. 2000;403:39-49. doi: 10.1111/j.1600-0447.2000.tb10947.x. Acta Psychiatr Scand Suppl. 2000. PMID: 11019934 Review.
Cited by
- Review of the current ongoing clinical trials exploring the possible anti-anxiety effects of cannabidiol.
Bhuller R, Schlage WK, Hoeng J. Bhuller R, et al. J Cannabis Res. 2024 Oct 12;6(1):40. doi: 10.1186/s42238-024-00250-y. J Cannabis Res. 2024. PMID: 39394179 Free PMC article. Review. - Clinical Efficacy and Mechanistic Insights of Anshen Dingzhi Prescription on Breast Cancer-Related PTSD Through Network Pharmacology and Molecular Docking.
Zhang H, Zhu Y, Zhu G, Yang S. Zhang H, et al. Integr Cancer Ther. 2024 Jan-Dec;23:15347354241285435. doi: 10.1177/15347354241285435. Integr Cancer Ther. 2024. PMID: 39344020 Free PMC article. - Attitudes and psychotropic preferences of primary care providers in the management of mental disorders: a web-based survey.
Örüm D. Örüm D. Front Med (Lausanne). 2024 Aug 1;11:1427745. doi: 10.3389/fmed.2024.1427745. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39149609 Free PMC article. - The effects of art therapy interventions on anxiety in children and adolescents: A meta-analysis.
Zhang B, Wang J, Abdullah AB. Zhang B, et al. Clinics (Sao Paulo). 2024 Jun 26;79:100404. doi: 10.1016/j.clinsp.2024.100404. eCollection 2024. Clinics (Sao Paulo). 2024. PMID: 38936289 Free PMC article. Review. - N-3 PUFA supplementation alleviates anxiety symptoms by manipulating erythrocyte fatty acid levels in depression.
Wang L, Liu T, Guo J, Zhao T, Tang H, Wang F, Dong F, Chen J, Tang M. Wang L, et al. Eur J Nutr. 2024 Sep;63(6):2271-2279. doi: 10.1007/s00394-024-03421-y. Epub 2024 May 17. Eur J Nutr. 2024. PMID: 38758363 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical